Nothing Special   »   [go: up one dir, main page]

WO1993013794A1 - Nouveaux procedes et compositions de traitement des maladies angiogeniques - Google Patents

Nouveaux procedes et compositions de traitement des maladies angiogeniques Download PDF

Info

Publication number
WO1993013794A1
WO1993013794A1 PCT/US1993/000677 US9300677W WO9313794A1 WO 1993013794 A1 WO1993013794 A1 WO 1993013794A1 US 9300677 W US9300677 W US 9300677W WO 9313794 A1 WO9313794 A1 WO 9313794A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
rpf4
synthetic
recombinant
medicament
Prior art date
Application number
PCT/US1993/000677
Other languages
English (en)
Inventor
Theodore E. Maione
Richard J. Sharpe
Original Assignee
Repligen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corporation filed Critical Repligen Corporation
Priority to JP5512743A priority Critical patent/JPH06506702A/ja
Publication of WO1993013794A1 publication Critical patent/WO1993013794A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • PF4 In addition to angiostatic properties, PF4 possesses characteristic structural features of the pro- inflammatory proteins interleukin-8 and ⁇ -thromboglobulin and has been shown to be chemotactic for neutrophils and monocytes in vivo (Wolpe and Cera i [1989] the FASEB Journal, 3:2565-2573). This similarity of the structure and activities of PF4 to well characterized pro- inflammatory proteins along with the ubiquitous aggregation of platelets at sites of inflammation suggest that PF4 may be an endogenous mediator of inflammation. Thus, it is anticipated that swelling could accompany the administration of PF4 in vivo. There is a significant and very long-standing need to locate an effective and non-toxic inhibitor of angiogenesis and endothelial cell proliferation. Angiogenesis plays a major role in the initiation and progression of widespread catastrophic illnesses, including cancer. An effective, non-toxic agent which can be administered locally and/or systemically to treat these illnesses would be highly advantageous and has long eluded identification.
  • conservative amino acid substitution means the substitution of an amino acid with another amino acid that is biologically compatible with the first amino acid.
  • PF4 has clinical utility in the treatment of diseases which involve angiogenesis and endothelial cell proliferation. Furthermore, PF4 fragments are demonstrated to be inhibitors of angiogenesis. The ability to inhibit angiogenesis has been found in synthetic peptides corresponding to sequences in PF4 as small as the carboxyterminal 13 amino acids.
  • the invention features treatment of angiogenic diseases with a combination of PF4 and an anti- inflammatory agent.
  • Anti-inflammatory agents help to alleviate unwanted swelling, pain, or tissue damage which could accompany the administration of pro-inflammatory compounds.
  • the invention also features methods for the treatment of tumors that contain malignant endothelial cells with PF4 either alone or in combination with an anti-inflammatory agent.
  • the invention features methods for the treatment of brain tumors with PF4.
  • Figure 1 shows DNA and amino acid sequence of native rPF4.
  • Figure 2 shows the inhibition of angiogenesis resulting from the treatment of rPF4 and various related peptides.
  • Figure 3 depicts the inhibition of endothelial cell proliferation by rPF .
  • Figure 5 compares the inhibition of angiogenesis resulting from treatment with rPF4 and rPF4-241.
  • Figure 6 compares the inhibition of human umbilical vein endothelial cell proliferation resulting from treatment with rPF4 or rPF4-241.
  • Figure 7 shows the ability of rPF4 and rPF4-241 to inhibit tumor growth.
  • Figure 8 shows footpad swelling in mice as a function of time after injection with either rPF4, rPF4 and indomethacin, or a buffer solution.
  • Figure 9 shows quantification of inflammatory cell infiltrate after treatment with rPF4 or rPF4 with indomethacin.
  • Advanced invasive malignancy with or without surgery, can be treated using the compositions and methods of the invention.
  • the invention can be used as an adjuvant therapy following surgical resection and can be used to treat known metastatic disease and nonmetastatic cancer.
  • Treatment of the tumors and diseases described above can be either systemic, regional, or local (intralesional) , depending upon the type and severity of the disease as well as the accessibility of the disease site.
  • Systemic treatment includes intravenous bolus injections and infusions, subcutaneous injections, implants, refillable reservoirs and sustained release depots and intramuscular injections.
  • Brain tumors are generally treated with initial surgical excision if possible, followed by intensive chemotherapy and radiation therapy.
  • Aggressive brain tumors (high grade astrocytoma, glioblastoma multiforme) ultimately produce mortality by reoccurrence near their original site due to incomplete surgical removal, rather than through metastatic dissemination.
  • Methods to specifically focus postsurgical treatment on the site of the initial lesion are therefore desirable to deliver effective therapy and reduce damage to healthy tissues.
  • the subject invention in part takes advantage of the ability of rPF4 to inhibit capillary formation in vivo as well as embryonic neovascularization. Full length recombinant PF4 also inhibits growth factor- dependent human endothelial cell proliferation in vitro.
  • PF4 directly inhibits growth of pure cultures of endothelial cells indicates that, advantageously, its effects are not mediated by some other cell type.
  • the activity of the C-13 peptide is especially surprising in light of its inability to affect the anticoagulant activity of heparin.
  • the use of the C-13 peptide offers several advantages over whole rPF4 such as reduced dosage (weight basis) , reduced likelihood of antigenicity, and greater likelihood of effectiveness in novel dosage forms.
  • the C-13 peptide of PF4 also retains the ability to prevent Con-A induced immunosuppression in mice, an activity which is unaffected by heparin and probably independent of the ability of the peptide to inhibit angiogenesis.
  • angiogenesis is required for solid tumors to grow beyond a few cubic millimeters.
  • use of rPF4, or a fragment thereof, to inhibit tumor growth by inhibiting angiogenesis presents a novel and highly advantageous means of therapy, although efficacy of PF4 in some of the therapies described herein is not entirely explained by inhibition of angiogenesis; for example, we have discovered that in specific types of cancers that contain malignant endothelial cells, such as Kaposi's sarcoma, PF4 was inhibitory.
  • the C-13 peptide inhibits angiogenesis without affecting the anticoagulant activity of heparin demonstrates that this small peptide would also have the benefit of not interfering with concurrent anticoagulant therapy.
  • small peptides are generally less antigenic than larger proteins, and, thus, the PF4 fragments can be used advantageously for oral and transdermal administration. These types of delivery are particularly useful in the treatment of gastrointestinal capillary proliferation (e.g., Kaposi's Sarcoma) and skin lesions, respectively. Intralesional, as well as systemic, administration of PF4 fragments are also appropriate for treatment of these conditions.
  • rPF4-241 Analogs of PF4 were created which lack heparin binding activity but retain ability to inhibit angiogenesis.
  • One such analog known as rPF4-241
  • rPF4-241 was created by cassette mutagenesis of a synthetic PF4 gene whereby the DNA sequence encoding the four lysine residues near the carboxy terminus of PF4 were converted to a sequence encoding two Gln-Glu couplets.
  • rPF4-241 is administered intralesionally, it can be applied such that the dosage is between about 1 ⁇ qflesion and about 4 mg/lesion.
  • dosages of rPF4 and fragments thereof may be twice that of rPF4-241 or higher.
  • PF4 has been shown to be chemotactic for neutrophils and monocytes m vitro, suggesting that it may mediate an inflammatory response.
  • rPF4 recombinant human PF4
  • Injection of an equivalent amount of cytochrome C, buffer alone, or an amino terminal PF4 peptide failed to elicit a significant inflammatory response, however, the carboxy terminal PF4 peptide was pro-inflammatory.
  • the rPF4 pro- inflammatory effect was significantly suppressed by systemic administration of an anti-inflammatory agent without reducing the angiostatic activity.
  • CAM Chicken Chorioallantoic Membrane Assay. Fertile eggs were incubated in a stationary position for 3 days at 37°C and 70-80% relative humidity. During this time, the embryo rose to the upper surface of the egg contents. At the beginning of the 4th day, the eggs were cracked without inversion and carefully deposited into sterile plastic petri dishes such that the embryo remained on the upper surface. The shell-free eggs were incubated for an additional 72 hours at 37°C, under an atmosphere containing 2.5-3.5% C0 2 after which the growing embryos developed a recognizable CAM. Discs, made by mixing test samples with 1% (w/v) methylcellulose, were dried and placed on the CAM between major veins and approximately 0.5 cm from the embryo.
  • Inhibition of DNA synthesis was measured by plating the cells as described, then incubating with the test substance for 24 hours. 3 H-Thymidine (1 ⁇ ,Ci/well) was added for an additional 6 hours and the plates were frozen at —70 C. Following 2 freeze/thaw cycles, the cells were aspirated onto a fiber filter, washed with distilled water, fixed with MeOH, and counted for incorporation of radioactivity into DNA.
  • rPF4 in preventing in vivo tumor growth and angiogenesis
  • tumor bearing animals were injected daily, directly into the nascent tumor, with either rPF4 or with buffer lacking rPF4, beginning one day after tumor inoculation.
  • Tumor volume was measured at regular intervals with digital calipers by laboratory personnel uninformed of the specific treatment received by each subject animal.
  • Footpad Assay 0.05 ml of PBS containing a test substance was injected intradermally into the right hind footpad of each mouse. An identical amount of diluent, not containing the test substance, was injected into the left hind footpad. At various time points, footpad thicknesses were measured with a spring loaded engineer's micrometer (Fowler Co., Biggswald, England).
  • mice were sacrificed and footpad tissue was prepared for light microscopy. This tissue was used to quantify infiltrating cell types. Biopsy specimens were fixed in 10% buffered formalin for at least 48 hours and then prepared using standard techniques of paraffin embedding and staining with hematoxylin and eosin. Using an ocular grid, four cellular areas of dermis in each specimen were examined in a coded fashion at 1000X magnification and inflammatory cells were quantified. Differences between groups were assessed by Student's t test or analysis of variance, where appropriate. rPF4 Production.
  • Cells expressing the fusion protein were subjected to lysozyme (1 mg/g cells) , DNase I (500 units/100 g cells) and bead mill treatments.
  • the lysis pellet containing the fusion protein was treated with CNBr (10 g/lOOg cells) in 70% formic acid to cleave the fusion protein at the methionine between the BG and PF4 portions.
  • CNBr 10 g/lOOg cells
  • the recombinant protein was extracted with 200 ml of 50 mM Tris-Cl, pH 7.6, 5 mM EDTA, and 10 mM DTT per 100 g of cell starting material.
  • Native sequence rPF4-211 was purified by binding the protein to heparin agarose, removing contaminating proteins with 0.6 M NaCl, and eluting with 1.2 M NaCl. The resulting material was dialyzed into 20 mM sodium acetate, pH 4.0, and analyzed on a 15% SDS-PA gel stained with Coomassie Brilliant Blue. Minor contaminants could be removed using C 4 reverse phase high pressure liquid chromatography (HPLC) to prepare the protein for in vivo use.
  • HPLC high pressure liquid chromatography
  • PF4 peptides Peptides were prepared by standard solid phase synthesis procedures, cleaved from the solid support and deblocked, and purified by reverse phase HPLC. Reagents. Recombinant human IL-1 (rIL-1) was purchased from Genzyme Corporation (Cambridge, MA) . Cytochrome c and J coli endotoxin were purchased from Sigma Chemical Co. (St. Louis, MO) . Slow release indomethacin pellets were purchased from Innovative Research (Toledo, OH) .
  • the lysine rich region of PF4 (residues 61-66) is also the domain associated with the binding of heparin by PF4.
  • Heparin is known to play a role in modulating angiogenesis, which can also be affected by protamine, another well characterized heparin-binding protein.
  • protamine another well characterized heparin-binding protein.
  • PF4-based synthetic peptides To assess the ability of PF4-based synthetic peptides to bind heparin, we assayed the activity of coagulation- cascade enzymes which are inhibited by heparin.
  • the Factor Xa assay used here has previously been described in Denton et al. (1983) Biochem. J. 209:455-460.
  • the protein was reactive with polyclonal antibodies to native PF4 and was determined to possess the appropriate modifications by amino acid analysis. Significantly, the purified mutant protein lacked 25 heparin-binding activity in the Factor Xa inhibition assay.
  • rPF4-241 was tested for its ability to 35 inhibit capillary growth in the chicken chorioallantoic membrane (CAM) assay. Even at the lowest concentrations tested (1.25 nmol/disc) rPF4-241 extensively inhibited angiogenesis in the CAM system ( Figure 5) . This inhibition was even more effective than that caused by equal concentrations of native rPF4 as suggested by larger avascular zones on the membrane. The inhibitory effect of rPF4-241 was not reversed by heparin.
  • CAM chicken chorioallantoic membrane
  • rPF4 as an inhibitor of angiogenesis, will possess clinical usefulness in the management of malignant melanoma and other cancers. Progressive growth of tumors requires new blood vessel formation which, if inhibited, may not only restrict tumor growth, but stimulate regression of . existing vessels, as well as enhance other responses to malignant invasion.
  • the finding that rPF4 inhibition of in vivo tumor growth was apparent within three days of the initial inoculation (of rPF4) indicates that rPF4 acts to modulate tumor growth by local mechanisms rather than by immunomodulation which would require a longer time course. Additionally, rPF4 did not directly inhibit tumor cell growth in vitro. It appears, therefore, that rPF4 modulated the host's angiogenic response to the growing tumor.
  • rPF4-302 which does not exhibit significant activity in either the CAM or the HUVEC assay, has no charged amino acid residues between residues 60 and 70.
  • rPF4-231 which also does not exhibit significant biological activity, terminates at amino acid number 60. If a person skilled in the art wished to investigate the biological activity of other rPF4 mutants, it would now be a straightforward procedure to make the desired mutations and test the resulting peptides for activity. Using the teachings of this document, the researcher could prepare and readily test peptides which could be expected to have the desired properties. For example, the amino acid substitutions just described for the full length rPF4 molecule can also be made with the C-13 and C-41 fragments which are described above.
  • Example 10 Inflammatory Properties of rPF4 and Related Compounds
  • the time course of rPF4 induced inflammation shows a rapid increase from baseline and peaks at between 6 and 12 hours and almost completely resolves by 36 hours.
  • Example 11 Effects of Anti-Inflammatory Agent with rPF4
  • 0.05 mg, slow release indomethacin pellets (Innovative Research, Toledo, OH) were implanted subcutaneously under light ether anesthesia 48 hours prior to an experiment. These pellets continuously release their contents over 14 days.
  • the non-steroidal anti-inflammatory agents include, but are not limited to, acetyl salicylic acid (aspirin) , methyl salicylate, sodium salicylate, phenylbutazone, oxyphenbutazone, apazone, indomethacin, sulindac, tol etin, mefenamic acid, ibuprofen, naproxen, fenoprofen, flurbiprofen, ketoprofen, and other compounds.
  • Other anti-inflammatory agents useful in the combinations and methods of this invention are lipocortins derived from natural sources or lipocortins and lipocortin-like polypeptides produced by recombinant techniques (see United States patent applications Serial Nos.
  • Steroidal anti-inflammatory agents which could be used according to the subject invention include, but are not limited to, hydrocortisones.
  • Example 12 Anti-Tumor Activity of rPF4 Combined with Indomethacin
  • mice Four groups of mice were used in this experiment. In two groups of mice, slow release indomethacin pellets (50 ⁇ g) were implanted surgically under the skin of the left flank. The other two groups were not treated with indomethacin. Tumors were implanted subcutaneously in all four groups in the right flank.
  • the combinations and methods of the present invention may allow the administration of PF4, or related compounds, in higher doses in some cases than those tolerated in conventional treatment regimes based upon PF4 alone. Accordingly, the combinations and methods of this invention advantageously reduce or eliminate the inflammatory effects of high dose treatments with PF4 alone. Thus, the use of PF4 in combination with an anti- inflammatory agent may reduce the duration of treatment which would be required by therapies based upon conventionally tolerated lower dosages of PF4 alone.
  • the combinations and methods of this invention are useful in treating any mammal, including humans.
  • mammals are treated with pharmaceutically effective amounts of the two active components—PF4 and an anti-inflammatory agent—of the combinations of this invention for a period of time sufficient to inhibit angiogenesis or endothelial cell proliferation.
  • the anti-inflammatory agent and the PF4 are administered sequentially to the patient, with the anti-inflammatory agent being administered before, after, or both before and after treatment with PF4.
  • Sequential administration involves treatment with the anti-inflammatory agent at least on the same day (within 24 hours) of treatment with PF4 and may involve continued treatment with the anti-inflammatory agent on days that the PF4 is not administered.
  • Conventional modes of administration and standard dosage regimens of anti- inflammatory agents may be used (see Gil an, A.G. et al. [eds.] The Pharmacological Basis of Therapeutics, pp. 697-713, 1482, 1489-91 [1980]; Physicians Desk Reference, 1986 Edition) .
  • indomethacin may be administered orally at a dosage of about 25-50 mg, three times a day. Higher doses may also be used.
  • aspirin about 1500-2000 mg/day
  • ibuprofen about 1200-3200 mg/day
  • conventional therapeutic doses of other anti-inflammatory agents may be used. Dosages of anti-inflammatory agents may be titrated to the individual patient.
  • Example 14 Dosages for Systemic Administration It has been discovered that very high doses of PF4 are required when PF4 is used systemically for treatment of tumors, and that these high doses do not have unacceptable high levels of toxicity. An experiment demonstrating the need for, and tolerance of, high doses of PF4 was carried out as follows.
  • PF4 produced a dose-dependent effect, as measured by both parameters. Optimal results were observed when PF4 was administered systemically, when dosages in excess of 5000 ⁇ g per kg of body weight; at these dosages, no observable toxicity or other adverse effects were noted.
  • Example 17 Systemic Treatment.
  • PF4 can be administered by direct intravenous injection, or preferably by intravenous infusion lasting from 0.5 to 4 hours per single treatment.
  • Patients can be treated as in- or out-patients. Patients may also be treated using implantable subcutaneous portals, reservoirs, or pumps. Multiple intravenous or subcutaneous doses are possible, and in the case of implantable methods for treatment, formulations designed for sustained release will be especially useful.
  • Patients can be treated at dosages of 0.3 to 12 g of rPF4 per period; preferably with 4 to 180 mg/kg in a volume of 60 ml to 2.5 liters per day.
  • a dosage is defined as a single dose administered as a bolus injection or intravenous infusion; or the compound can be administered to the patient as an intravenous infusion over a period of a day; alternatively, the compound can be administered in several bolus injections interrupted by periods of time such that the dose is delivered over the course of a 24 hour period.
  • the most preferred method of treatement is to administer the compound to the patient in one injection or infusion per day.
  • Patients may be treated daily on alternative weeks for six weeks, or possibly for life. They may also be treated three times per week continuously, or they may be treated daily for life.
  • PF4 or related compounds may be administered to the patient in any pharmaceutically acceptable dosage form, including intravenous, intramuscular, intralesional, or subcutaneous injection.
  • An effective dose may be in the range of from about 0.003 to about 200 mg/kg body weight, it being recognized that lower and higher doses may also be useful. As discussed above, very high doses are preferred for systemic administration. It should, of course, be understood that the compositions and methods of this invention may be used in combination with other therapies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions et procédés de traitement de l'angiogénèse à l'aide du facteur plaquettaire 4 et de ses fragments peptidiques.
PCT/US1993/000677 1992-01-16 1993-01-19 Nouveaux procedes et compositions de traitement des maladies angiogeniques WO1993013794A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5512743A JPH06506702A (ja) 1992-01-16 1993-01-19 脈管形成性の病気の処置用の新規な方法と組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82237892A 1992-01-16 1992-01-16
US822,378 1992-01-16

Publications (1)

Publication Number Publication Date
WO1993013794A1 true WO1993013794A1 (fr) 1993-07-22

Family

ID=25235857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000677 WO1993013794A1 (fr) 1992-01-16 1993-01-19 Nouveaux procedes et compositions de traitement des maladies angiogeniques

Country Status (5)

Country Link
EP (1) EP0576669A4 (fr)
JP (1) JPH06506702A (fr)
AU (1) AU3592593A (fr)
CA (1) CA2106368A1 (fr)
WO (1) WO1993013794A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013823A1 (fr) * 1992-12-10 1994-06-23 Z. Company S.A. Sequence nucleotidique destinee au traitement du cancer et des infections
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
WO1996025171A1 (fr) * 1995-02-16 1996-08-22 F.Hoffmann-La Roche Ag Inhibition de l'angiogenese a l'aide de l'interleukine-12
US5639727A (en) * 1993-03-12 1997-06-17 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5763567A (en) * 1993-03-12 1998-06-09 Xoma Corporation Biologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof
AU705080B2 (en) * 1995-11-15 1999-05-13 Antti Aarne Ilmari Lange Method for adaptive kalman filtering in dynamic systems

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287183A1 (fr) * 2009-07-29 2011-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
EP0281363A2 (fr) * 1987-03-02 1988-09-07 Oncogen Régulateur de croissance lie aux plaquettes sanguines
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン　コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
CA2113206A1 (fr) * 1991-07-15 1993-02-04 Theodore E. Maione Compositions de pf4 modifie et methodes d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
EP0281363A2 (fr) * 1987-03-02 1988-09-07 Oncogen Régulateur de croissance lie aux plaquettes sanguines
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Research, Volume 51, issued 15 April 1991, MAIONE et al., "Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity", pages 2077-2083, see page 2077, 2078 and 2083. *
Science, Volume 235, issued 23 January 1987, FOLKMAN et al., "Angiogenic Factors", pages 442-447, see pages 442 and 446. *
See also references of EP0576669A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013823A1 (fr) * 1992-12-10 1994-06-23 Z. Company S.A. Sequence nucleotidique destinee au traitement du cancer et des infections
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5639727A (en) * 1993-03-12 1997-06-17 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5763567A (en) * 1993-03-12 1998-06-09 Xoma Corporation Biologically active peptides from funcional domains of bactericidal/permeability-increasing protein and uses thereof
US5807818A (en) * 1993-03-12 1998-09-15 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein (BPI) protein products
US5837678A (en) * 1993-03-12 1998-11-17 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5854214A (en) * 1993-03-12 1998-12-29 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
WO1996025171A1 (fr) * 1995-02-16 1996-08-22 F.Hoffmann-La Roche Ag Inhibition de l'angiogenese a l'aide de l'interleukine-12
AU705080B2 (en) * 1995-11-15 1999-05-13 Antti Aarne Ilmari Lange Method for adaptive kalman filtering in dynamic systems

Also Published As

Publication number Publication date
JPH06506702A (ja) 1994-07-28
AU3592593A (en) 1993-08-03
CA2106368A1 (fr) 1993-07-17
EP0576669A1 (fr) 1994-01-05
EP0576669A4 (en) 1996-05-08

Similar Documents

Publication Publication Date Title
US5284827A (en) Systemic treatment of metastatic cancer with platelet factor 4
WO1992002240A2 (fr) Compositions et procedes nouveaux pour le traitement des maladies angiogeniques
EP0407122B1 (fr) Compositions de PF4 modifié et méthode d'utilisation
US5474981A (en) Use of the cytokine IP-10 as an anti-tumor agent
US5800820A (en) Methods and compositions for treatment of angiogenic diseases
JP4384597B2 (ja) キメラコイルドコイル分子
EP1038011B1 (fr) Procede de production de proteines anti-angiogeniques, dont l'endostatine, l'angiostatine ou la restine, au moyen d'un systeme d'expression de la levure pichia
EP0379522B1 (fr) Utilisations du facteur-1 recombinant de stimulation de colonie
WO1993013794A1 (fr) Nouveaux procedes et compositions de traitement des maladies angiogeniques
AU2004285847A1 (en) Antiangiogenicpeptides for treating or preventing endometriosis
EP0739354B1 (fr) Compositions et methodes utilisant un recepteur mpl non lie pour stimuler la production de plaquettes
WO1993002192A1 (fr) Compositions pf4 et procedes d'utilisation desdites compositions
US6797488B1 (en) Methods of producing anti-angiogenic proteins
US8133491B1 (en) Compositions and methods for treatment of hyperplastic disorders
CN114605501B (zh) 一种可拮抗fus蛋白rna结合活性的多肽fip-21及其应用
JP2000095702A (ja) サルモシンを有効成分として含む抗ガン剤
WO1988002632A1 (fr) Combinaisons de facteurs de necroses de tumeurs et d'agents anti-inflammatoires, et procedes de traitement de maladies malignes et non malignes
WO2011119008A2 (fr) Peptides pour favoriser l'angiogenèse et leur utilisation
WO2001010899A2 (fr) Traitement de maladies et de lesions hepatiques avec des chimiokines cxc
EP1196440B1 (fr) Peptidiques therapeutiques derives de subsequences de bpi
JP4583763B2 (ja) 切断型２４ｋＤａ塩基性線維芽細胞成長因子

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/10-1/10,DRAWINGS,REPLACED BY NEW PAGES 1/10-1/10;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2106368

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993904627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993904627

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993904627

Country of ref document: EP